- ICH GCP
- Register voor klinische proeven in de VS.
- Klinische proef NCT00814476
The Effects of Regular Home Use Vs Diabetic Team- Supported Use of the Medtronic CareLink Therapy Management System. (CareLink)
The Efficacy, Short and Long Term Effects of Regular Home Use Vs Diabetic Team - Supported Use of the Medtronic CareLink Therapy Management System in Patients With Diabetes
Studie Overzicht
Toestand
Conditie
Gedetailleerde beschrijving
A randomized, two arms, controlled, open study in order to compare the efficacy, short and long term effects of regular home-use Vs diabetic team- supported use of the Medtronic CareLink therapy management system in patients with diabetes.
Primary objective:
To assess the efficacy, short term (4 months) and long term (8 months) effects of using the Medtronic CareLink® Therapy Management System for Diabetes on the following parameters:
- Metabolic control as expressed by HbA1c.
- Hypoglycemic events- number and severity of episodes.
- DKA and ketosis events- number and severity of episodes.
- Patient's satisfaction and quality of life measured by treatment satisfaction and quality of life questionnaires.
- 7 points glucose profile.
Secondary objective:
To compare the efficacy of 4 months treatment using the CareLink® Therapy Management System, accompanied with intensive contact (at least once a month) initiated by diabetic team via the internet/electronic mail Vs home use treatment - without monthly contact initiated by the diabetic team
Study design:
The study will be comprised of two consecutive segments. At the first segment that will last during the first 4 months of the study, patients will be randomized to the CareLink treated group or non CareLink treated group. At this segment of the study the usage of the CareLink system will be accompanied by the diabetic team, through at least monthly contact via the internet initiated by the diabetic team. At the second segment of the study, during the following 4 months, both groups will use the CareLink system, home-use, without support initiated by the diabetic team.
Studietype
Inschrijving (Werkelijk)
Fase
- Fase 4
Contacten en locaties
Studie Locaties
-
-
-
Petach-Tikva, Israël
- Schnider children medical center
-
-
Deelname Criteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
Accepteert gezonde vrijwilligers
Geslachten die in aanmerking komen voor studie
Beschrijving
Inclusion Criteria:
- Type 1 diabetes diagnosed at least 6 months prior to study entry
- Current treatment with Medtronic 722 /712 external insulin pump systems
- Treatment with insulin pump at least 3 month prior to study entry
- An internet access from patient's home
- Age 0-35 years old
- HbA1c>7.8
- Signing inform consent forms
Exclusion Criteria:
- Any significant disease or conditions, including psychiatric disorders that in the opinion of the investigator are likely to effect his compliance or ability to complete the study
- Patients participating in other device or drug studies
Studie plan
Hoe is de studie opgezet?
Ontwerpdetails
- Primair doel: Ondersteunende zorg
- Toewijzing: Gerandomiseerd
- Interventioneel model: Parallelle opdracht
- Masker: Geen (open label)
Wapens en interventies
Deelnemersgroep / Arm |
Interventie / Behandeling |
---|---|
Actieve vergelijker: 2
Regular treated group in the first segment and CareLink treated group in the second segment
|
At the first 4 months patients will continue at their regular treatment and contacts initiated by the study team via internet/electronic mail will be made once a month.
At the second segment of the study patients there will be home use of the CareLink System until the end of the study.
No further contact will be initiated by the study team.
|
Experimenteel: 1. CareLink team supported group
CareLink team supported group
|
At the first segment, the usage of the CareLink system will be accompanied by the diabetic team, through at least monthly contact via the internet initiated by the diabetic team.
In the second phase of the study,during the following 4 months, there will be regular home use of the CareLink system, without support initiated by the diabetic team
|
Wat meet het onderzoek?
Primaire uitkomstmaten
Uitkomstmaat |
Tijdsspanne |
---|---|
HbA1c
Tijdsspanne: At Baseline and every 4 month after
|
At Baseline and every 4 month after
|
Secundaire uitkomstmaten
Uitkomstmaat |
Tijdsspanne |
---|---|
Hypoglycemic events
Tijdsspanne: will be recorded through the whole study period
|
will be recorded through the whole study period
|
DKA and ketosis events
Tijdsspanne: will be recorded through the whole study period
|
will be recorded through the whole study period
|
Patient's satisfaction and quality of life questionnaire
Tijdsspanne: At baseline visit and every 4 months after
|
At baseline visit and every 4 months after
|
7 points glucose profile
Tijdsspanne: Will be recorded 2 days before baseline visit and every 4 months after
|
Will be recorded 2 days before baseline visit and every 4 months after
|
Medewerkers en onderzoekers
Sponsor
Studie record data
Bestudeer belangrijke data
Studie start
Primaire voltooiing (Werkelijk)
Studie voltooiing (Werkelijk)
Studieregistratiedata
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Schatting)
Updates van studierecords
Laatste update geplaatst (Schatting)
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Aanvullende relevante MeSH-voorwaarden
Andere studie-ID-nummers
- rmc005047ctil
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .
Klinische onderzoeken op Diabetes type 1
-
University of Colorado, DenverMassachusetts General Hospital; Beta Bionics, Inc.VoltooidDiabetes mellitus, type 1 | Diabetes type 1 | Diabetestype1 | Diabetes mellitus type 1 | Auto-immuun diabetes | Diabetes Mellitus, insulineafhankelijk | Jeugddiabetes | Diabetes, auto-immuunziekte | Insulineafhankelijke diabetes mellitus 1 | Diabetes Mellitus, insulineafhankelijk, 1 | Diabetes Mellitus,... en andere voorwaardenVerenigde Staten
-
Capillary Biomedical, Inc.VoltooidDiabetes mellitus, type 1 | Diabetes type 1 | Diabetes mellitus type 1 | Diabetes Mellitus, insulineafhankelijk, 1Australië
-
Poznan University of Medical SciencesOnbekendDiabetes mellitus type 1 | Remissie van diabetes type 1 | Chronische complicaties van diabetesPolen
-
University of California, San FranciscoJuvenile Diabetes Research FoundationVoltooidDiabetes mellitus type 1 | Diabetes mellitus, type I | Insulineafhankelijke diabetes mellitus 1 | Diabetes Mellitus, insulineafhankelijk, 1 | IDDMVerenigde Staten, Australië
-
Capillary Biomedical, Inc.BeëindigdDiabetes type 1 | Diabetes mellitus type 1 | Diabetes mellitus, type I | Diabetes Mellitus, insulineafhankelijk, 1 | IDDMOostenrijk
-
National Institute of Allergy and Infectious Diseases...PPD; Rho Federal Systems Division, Inc.; Immune Tolerance Network (ITN)VoltooidDiabetes mellitus type 1 | T1DM | T1D | Nieuwe diabetes mellitus type 1Verenigde Staten, Australië
-
Eledon PharmaceuticalsIngetrokkenBroze type 1 diabetes mellitusVerenigde Staten
-
Shanghai Changzheng HospitalWervingBroze type 1 diabetes mellitusChina
-
University Hospital Inselspital, BerneVoltooidDiabetes complicaties | Diabetes mellitus type 1Zwitserland
-
Spiden AGDCB Research AGVoltooidDiabetes mellitus type 1 | Diabetes mellitus type 1 met hypoglykemie | Diabetes mellitus type 1 met hyperglykemieZwitserland